Ahead of the launch of their new Produodopa in Parkinson's disease (PD), Abbvie wanted to challenge neurologists on the burden of oral treatment to patients with complex or advanced PD and when is it time to consider non-oral medication. Patients on oral treatment take a lot of tablets, and we created the 5-2-1 device as a marker for action, to highlight when oral treatments were starting to fail, with a CTA of 'It's time to talk' to your PD patient.
5-2-1 stands for >5 times a day oral medication is taken, >2 hours of 'OFF' time, when patients can freeze up, and >1 hour a day of dyskinesia, the rapid uncontrolled body movement.
OOH congress comms
Downloadable content from website
Targeted emails